Company Description
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.
Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam.
The company was incorporated in 2013 and is headquartered in Pudong, China.
| Country | China |
| Founded | 2013 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,869 |
| CEO | Ying Du |
Contact Details
Address: Building B, 899 Halei Road Pudong, 201203 China | |
| Phone | 86 21 6163 2588 |
| Website | zailaboratory.com |
Stock Details
| Ticker Symbol | ZLAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704292 |
| CUSIP Number | 98887Q104 |
| ISIN Number | US98887Q1040 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
| Joshua L. Smiley | President and Chief Operating Officer |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research and Development |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Frazor Titus Edmondson III, J.D. | Chief Legal Officer and Corporate Secretary |
| Christine Chiou | Senior Vice President and Head of Investor Relations |
| Dr. Jonathan J. Wang MBA, Ph.D. | Chief Business Officer |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Research & Development |
| Tong Zhu | Chief Commercial Officer of Greater China |
| Dr. Robert J. Brown M.D. | Chief Medical Officer of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 144 | Filing |
| Aug 8, 2025 | 144 | Filing |
| Aug 8, 2025 | 144 | Filing |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jun 30, 2025 | 144 | Filing |
| Jun 26, 2025 | 144 | Filing |
| Jun 26, 2025 | 144 | Filing |